Tag: HER2-Positive Biliary Tract Cancer

Home / HER2-Positive Biliary Tract Cancer

Categories

Zanidatamab-hrii is approved by the USFDA for previously treated unresectable or metastatic HER2-positive biliary tract cancer

 On November 20, 2024, the Food and Drug Administration granted accelerated approval for zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-targeted antibody, for previously tr...
her2-positive-biliary-tract-cancer

Scan the code